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Objective: To determine and compare failure, re-operation, and complication rates of all generations and
techniques of autologous chondrocyte implantation (ACI).
Methods: A systematic review of multiple medical databases was performed according to PRISMA
guidelines. Levels IeIV evidence were included. Generations of ACI and complications after ACI were
explicitly deﬁned. All subject and defect demographic data were analyzed. Modiﬁed Coleman Method-
ology Scores (MCMSs) were calculated for all studies.
Results: 82 studies were identiﬁed for inclusion (5276 subjects were analyzed; 6080 defects). Ninety
percent of the studies in this review were rated poor according to the MCMS. There were 305 failures
overall (5.8% subjects; mean time to failure 22 months). Failure rate was highest with periosteal ACI
(PACI). Failure rates after PACI, collagen-membrane cover ACI (CACI), second generation, and all-
arthroscopic, second-generation ACI were 7.7%, 1.5%, 3.3%, and 0.83%, respectively. The failure rate of
arthrotomy-based ACI was 6.1% vs 0.83% for all-arthroscopic ACI. Overall rate of re-operation was 33%.
Re-operation rate after PACI, CACI, and second-generation ACI was 36%, 40%, and 18%, respectively.
However, upon exclusion of planned second-look arthroscopy, re-operation rate was highest after PACI.
Unplanned re-operation rates after PACI, CACI, second-generation, and all-arthroscopic second-genera-
tion ACI were 27%, 5%, 5%, and 1.4%, respectively. Low numbers of patients undergoing third-generation
ACI precluded comparative analysis of this group.
Conclusions: Failure rate after all ACI generations is low (1.5e7.7%). Failure rate is highest with PACI, and
lower with CACI and second-generation techniques. One out of three ACI patients underwent a re-
operation. Unplanned re-operations are seen most often following PACI. Hypertrophy and delamination
is most commonly seen after PACI. Arthroﬁbrosis is most commonly seen after arthrotomy-based ACI.
Use of a collagen-membrane cover, second-generation techniques, and all-arthroscopic, second-gener-
ation approaches have reduced the failure, complication, and re-operation rate after ACI.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Full-thickness chondral defects in the knee lack the intrinsic
ability for complete spontaneous repair. It is generally agreed that
these defects have the potential to progress to osteoarthritis with
pain and loss of function. Several surgical options exist to address
these lesions. First-generation autologous chondrocyte implantationD.C. Flanigan, The Ohio State
ation Program, 2050 Kenny
614-293-3600.
lanigan).
s Research Society International. P(ACI) is a technique that is indicated for the repair of symptomatic
cartilage defects of the distal femur in patients who have had an
inadequate response to a prior arthroscopic or surgical repair
procedure (e.g., debridement, microfracture, drilling, abrasion
arthroplasty, or osteochondral autograft/allograft)1,2.
Despite successful clinical outcomes, re-operation rates for
symptomatic hypertrophy of the periosteal graft used in ﬁrst-
generation ACI have been up to nearly 40%3. Complications recently
reported to the United States Food and Drug Administration (FDA)
include failure of the graft, graft delamination, tissue hypertrophy,
chondromalacia, adhesions, loose bodies, arthroﬁbrosis, and
several others1. Overall, nearly 90% of patients who have a compli-
cation experience one of the following: transplant hypertrophy,ublished by Elsevier Ltd. All rights reserved.
Table I
Inclusion and exclusion criteria for study analysis
Inclusion criteria Exclusion criteria
English language studies Non-English language studies
Human subjects Animal studies, basic science studies, biomechanical studies
Clinical studies reporting complications following ACI Clinical studies of ACI not reporting complications
All generations of ACI Clinical studies of autologous bone-marrow-derived mesenchymal
stem cell implantation
Open and arthroscopic implantation of cells Clinical studies of autologous matrix-induced chondrogenesis
Knee joint only (femoral condyles, trochlea, patella, tibial plateau) Joints other than the knee
Level I, II, III, IV evidence, including isolated case reports of unique
or rare complications
Level V evidence
Address Outerbridge/ICRS grade III or IV chondral or osteochondral defects
Search performed on May 1, 2010. ICRS (International Cartilage Repair Society).
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articular cartilage, insufﬁcient regenerative cartilage, or graft
delamination4. Collagen-membrane covers were developed to
avoid periosteal harvest which serves to reduce overall post-oper-
ative pain and reduces surgical time. The incidence of symptomatic
hypertrophy has been reduced with the development of collagen-
membrane cover ACI (CACI)5. All-arthroscopic implantation of
cultured chondrocytes has been developed to reduce further the
risk of complications and re-operation related to ﬁrst-generation
techniques6.
The purpose of this review was to systematically review the
literature reporting clinical outcomes and complications after ACI
and answer the questions: (1) What is the prevalence of failures
after ACI, (2) What is the prevalence of re-operations after ACI, (3)
What is the prevalence and description of complications after ACI?
The latter were then compared across different generations of ACI
and between open and all-arthroscopic techniques.
We hypothesized that complications, re-operations, and failures
are more commonly seen after periosteal-cover, ﬁrst-generation
ACI, particularly with arthrotomy, compared with later generation
ACI using arthroscopic techniques.Fig. 1. Systematic review search algorithm within Medline database according to
PRISMA guidelines. After application of all inclusion and exclusion criteria, 82 studies
were identiﬁed for review.Methods
We conducted a systematic review of the available literature
according to PRISMA (Preferred Reporting Items for Systematic
reviews andMeta-analyses) guidelines with a PRISMA checklist. Six
independent reviewers (JH, RS, RB, CL, JC, DF) separately completed
the search. The search was performed on May 1, 2010. The
following databases were utilized: Medline (1950 e May 1, 2010),
CINAHL (1994 e May 1, 2010), SPORTDiscus (1975 e May 1, 2010),
and Cochrane Central Register of Controlled Trials (1994 e second
quarter 2010). Search terms included: knee, ACI, ACT, autologous,
autogenous, chondrocyte, articular cartilage, implantation, trans-
plantation, complication(s), failure(s), re-operation(s), and adverse
events. Levels I, II, III, and IV evidence (according to the Oxford
Centre for Evidence Based Medicine used by the American version
of the Journal of Bone and Joint Surgery)7 English language studies
were included (Table I). Both print journal and e-published articles
were eligible for inclusion. Scientiﬁc conference abstracts were not
eligible for inclusion. If there was any disagreement among authors
regarding inclusion of an article, the senior author (DF) made the
ﬁnal decision. All references within included studies were assessed
for potential inclusion if missed by the initial search. In the
circumstance of duplicate studies that analyzed the same pop-
ulation of subjects, only the more recent publication was retained.
Figure 1 illustrates a ﬂow diagram of our search citation strategy.
ACI inter-generational comparisons were made based on deﬁ-
nitions of techniques previously reported (Table IIa). First-genera-
tion ACI, originally reported by Brittberg et al. in 19948, was deﬁnedas a two-stage (ﬁrst stage arthroscopic biopsy and second stage
open or mini-open arthrotomy) procedure with implantation of
cultured chondrocytes under a periosteal ACI (PACI) or type IeIII
porcine collagen-derived (CACI) cover. Characterized chondrocyte
implantation (CCI) is also designated as a ﬁrst-generation tech-
nique based on its open, second stage, subperiosteal-cover
implantation of cultured chondrocytes. Table IIb lists all PACI, CACI,
and CCI techniques included.
Second-generation ACI9 was deﬁned as a two-stage procedure
(either arthroscopic biopsy ﬁrst stage and open arthrotomy second
stage or arthroscopic biopsy ﬁrst stage and arthroscopic implan-
tation second stage) with implantation of cultured chondrocytes
via cell-seeded, three-dimensional, bioabsorbable scaffolds.
Table IIb lists all second-generation techniques included. Prior
chondrocyte seeding and the ability for secure graft ﬁxation
Table IIa
Generations of ACI
First-generation ACI Second-generation ACI Third-generation ACI
PACI MACI NeoCart
CACI Hyalograft C VeriCart
CCI BioSeed C DeNovo NT
CaReS DeNovo ET
NovoCart 3D CAIS
Cartipatch
TissuCol
IP-CHA-atellocollagen gel
Chondron
ACI-Maix
MACI (matrix-associated or matrix-induced ACI); CAIS (cartilage autograft implan-
tation system).
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thus allows for all-arthroscopic implantation10.
Third-generation ACI was deﬁned as either one-stage or two-
stage, open or arthroscopic, ACI with implantation of in-vitro-
treated autologous chondrocytes within “chondro-inductive and
chondro-conductive,” three-dimensional matrices. Table IIb lists
the third-generation techniques included.
After ACI, all adverse events voluntarily reported by physicians
and obligatory reported by manufacturers are monitored by the
FDA. Analysis of adverse events after ACI have been grouped into 16
nonmutually exclusive categories1. Further, re-operations were
grouped into ﬁve categories1. AE’s assessed included graft failure,
delamination, tissue hypertrophy, chondromalacia, adhesions,Table IIb
Descriptions of ﬁrst-, second- and third-generation ACI techniques
Technique Descr
First generation PACI [Carticel (Genzyme Biosurgery, Boston,
Massachusetts, USA)8
Two-s
CACI [ChondroGide or BioGide (Geistlich Biomaterials,
Wolhusen, Switzerland)]5
Two-s
collag
CACI [Restore (DePuy, Warsaw, Indiana, USA)] Two-s
collag
CACI [Pegasus (Pegasus Biologics, Irvine, California, USA)] Two-s
collag
CCI [ChondroCelect (Tigenix NV Inc., Leuven, Belgium)]27 Propr
of a h
Second
generation
MACI (Verigen, Copenhagen, Denmark)61 Utilize
scaffo
cultur
Hyalograft C (HYAFF-11, Fidia Advanced Biopolymers
Laboratories, Padova, Italy)10
Utilize
chond
BioSeed C (TransTissue Technologies GmbH, BioTissue
Technologies GmbH)48
Utilize
resorb
CaReS (Arthro Kinetics, Esslingen, Germany) Utilize
Novocart 3D (TETEC Tissue Engineering Technologies
AG, Reutlingen, Germany)
Utilize
perica
Cartipatch (TBF Genie Tissulaire, Bron, France) Utilize
TissuCol (Baxter, Austria)76 Utilize
IP-CHA-atellocollagen gel (Koken, Tokyo, Japan) Utilize
chond
Chondron (Sewon Cellontech Co. Ltd., Seoul, South Korea)36 Utilize
ACI-Maix (Matricel GmbH, Germany) Utilize
Third
generation
NeoCart (Histogenics, Waltham, Massachusetts, USA)20 Utilize
embe
VeriCart (Histogenics, Waltham, Massachusetts, USA) May b
chond
or allo
be use
chond
CAIS (DePuy Mitek, Raynham, Massachusetts, USA) May b
distrib
and se
MACI (matrix-associated or matrix-induced ACI); CAIS (cartilage autograft implantationloose bodies, meniscal tear, local infection, patellar maltracking,
arthroﬁbrosis, plica formation, pain, hematoma/hemarthrosis, and
others1. Failure was variably deﬁned across studies (Table III). The
complications hypertrophy, symptomatic hypertrophy, delamina-
tion, and chondromalacia were also variably deﬁned across studies
(Table III). The reporting of failures, re-operations, and complica-
tions after any generation of ACI within a study warranted inclusion
in this systematic review. Missing information pertinent to these
parameters warranted exclusion from this review. All information
utilized in this review was extracted from studies. No attempts
were made to contact individual study authors due to the large
number of studies analyzed. No assumptions or simpliﬁcations
were made regarding any data within the studies analyzed. All data
were extracted and recorded literally verbatim. With the data
collection process, the authors recorded all study, patient, surgical
technique, and adverse event variables in a data ﬁle in Microsoft
Excel unique to the parameters of this study (Appendix 1).
Bias and study methodological quality were assessed with the
Modiﬁed ColemanMethodology Score (MCMS)was used (Appendix
2A). This 15-item instrument is a scaled potential score from 0 to
100. Scores from 85 to 100 are excellent, 70e84 are good, 55e69 are
fair, and less than 55 are poor. Further,MCMS scoreswere compared
based on date of study publication, level of evidence, and the
presence or absence of a ﬁnancial conﬂict of interest (COI).
Descriptive statistics were calculated. Continuous variable data
were reported as mean standard deviations from the mean. Data
range was reported as minimum to maximum. Categorical variable
data was reported as frequency with percentages. For all statisticaliption
tage, open arthrotomy implantation of cells beneath autologous periosteal-cover
tage, open arthrotomy implantation of cells beneath type IeIII porcine
en-derived (CACI) cover
tage, open arthrotomy implantation of cells beneath type IeIII porcine
en-derived (CACI) cover
tage, open arthrotomy implantation of cells beneath type IeIII porcine
en-derived (CACI) cover
ietary genetic marker proﬁle score (CC score) that optimizes the likelihood
yaline phenotype and its associated biological, cartilage-forming capability
s same type IeIII porcine collagen-derived membrane (ChondroGide) as
ld for in-vitro-cultured cell seeding with subsequent autologous serum
e prior to seeded scaffold in-vivo implantation
s a hyaluronic acid-based scaffold, seeded with in-vitro-cultured
rocytes prior to in-vivo implantation
s a ﬁbrin gel-polymer matrix seeded in-vitro prior to implantation and is
ed over 2e3 months32
s a type I collagen gel matrix seeded in-vitro prior to implantation
s a biphasic chondroitin sulfate-collagen scaffold (derived from bovine
rdium) seeded in-vitro prior to implantation
s a solid agarose-alginate matrix seeded in-vitro prior to implantation
s chondrocytes seeded on tissue ﬁbrin glue
s hydroxyapatite with interconnected pores scaffold seeded with
rocytes embedded in 3% type I collagen atellocollagen gel
s a chondrocyte-pre-seeded ﬁbrin three-dimensional matrix gel
s a chondrocyte-pre-seeded type I/III collagen membrane as scaffold
s two stages and implants autologous cells processed in a bioreactor and
dded upon a bovine type I collagen matrix
e placed in one surgery and utilizes a collagen matrix that may allow for
rocyte migration into the matrix or support rehydration with autologous
genic stem cells harvested and implanted at the time of surgery (may also
d in conjunction with microfracture via AMIC [autologous matrix-induced
rogenesis])
e placed in one surgery and utilizes minced autologous hyaline cartilage,
uted on a three-dimensional polyglycolic acid-polycaprolactone scaffold
cured via absorbable polydiaxonone staples
system).
Table III
Variable deﬁnitions of failure, hypertrophy, symptomatic hypertrophy, delamination, chondromalacia, and re-operation
Complication Description
Failure Any case requiring re-operation due to symptoms related to the primary defect14,22,27
Any case with greater than 20e25% of grafted defect area had to be removed in later procedures due to persistent symptoms31,40
Re-operation/reintervention requiring graft removal, conﬁrmation of no ﬁll, graft delamination, or subsequent treatment
violating subchondral bone or repeat ACI5,15,24
Re-operation via revision to arthroplasty24,26,31 or osteochondral allograft26
If patient-reported overall knee condition score (modiﬁed Cincinnati Knee Rating System) failed to improve from baseline
during three consecutive 6-month intervals29
MRI evidence of graft delamination24,26,45
Biopsy evidence of ﬁbrocartilage or non-cartilage27
Formation of insufﬁcient regenerative cartilage4
Revision surgery with other resurfacing techniques
ICRS objective scores that were “severely abnormal” on the grounds of limited range-of-motion, painful retropatellar
crepitations, persistent effusions39
When bare bone was seen in less than 50% of repair (partial failure) or greater than 50% of repair (total failure)56
Lysholm knee score <6068
Several studies reported failure without clearly deﬁning it37
Hypertrophy Direct observation via arthroscopy
Indirect observation via MRI
Overﬁlling with loss of continuous cartilage surface thickness56
Graded by the degree of elevation above the adjacent normal articular cartilage55
Symptomatic hypertrophy Pain with mechanical symptoms such as persistent popping, catching, or clicking in a location corresponding to a previous
ACI graft site and conﬁrmed by MRI5
Delamination4 Malfusion of neocartilage to surrounding normal, host articular cartilage
Early partial delamination
Eventual late ﬂap formation
Complete delamination and detachment, preceding loose body formation
Chondromalacia16 By name (within individual studies without a deﬁnition or description)
Defect ﬁll <50% of total volume or area (by MRI)
Appearance of a new chondral defect
Re-operation5,78 Any subsequent revision procedure following ACI, planned (second-look arthroscopy, biopsy) or unplanned (symptom-based),
including manipulation under anesthesia, arthroscopy, or arthrotomy
Planned re-operation Subsequent surgical procedure following ACI that was a-priori determined to be performed at a speciﬁc date following
chondrocyte implantation
ICRS (International Cartilage Repair Society).
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comparisons of PACI vs CACI, ﬁrst generation vs second generation,
and open arthrotomy-based vs all-arthroscopic ACI, a two-
proportion Z-test was calculated to determine whether the differ-
ence between the two proportions was signiﬁcant. The sample
proportion difference (population mean P0) between groups was
deﬁned as zero (null hypothesis is true). This calculation was per-
formed for failure, unplanned re-operation, hypertrophy, delami-
nation, and arthroﬁbrosis rates after all generations of ACI.Table IVa
Subject distribution across levels of evidence
Level of
evidence
Number of
studies
reporting ACI
Number of
subjects
undergoing ACI
Number of
knees
undergoing ACI
Number of
defects
undergoing ACI
I 7 270 270 275
II 12 1074 1078 1164
III 10 1002 1007 1088
IV 53 2930 2997 3553
82 5276 5352 6080Results
Eighty-two studies were identiﬁed for inclusion3e6,11e88.
Tables IVa and IVb displays the distribution of subjects within each
generation of ACI. Forty-one percent (n¼ 34; 34/82) of studies
declared a ﬁnancial COI, 37% (n¼ 30; 30/82) denied a COI, and 22%
(n¼ 18; 18/82) did not report the presence or absence of a COI.
First-generation ACI studies (27/60; 45%) were signiﬁcantly more
likely to declare a COI than second-generation studies (7/28; 25%)
(Z¼ 1.79; P¼ 0.04). There was no signiﬁcant difference between
ﬁrst- (12/60; 20%) and second- (8/28; 29%) generation techniques
in the lack of declaring either the presence or absence of a COI
(Z¼0.93; P¼ 0.17). Table V describes all patient and defect
demographic data. Mean follow-up after ﬁrst-generation PACI was
3.65 years (2758 subjects), after ﬁrst-generation CACI was 3.77
years (399 subjects), after second-generation ACI was 2.61 years
(888 subjects), and after third generation ACI was 2 years
(8 subjects). Overall, mean follow-up was 3.27 years.Study methodological quality
Mean MCMS was 35.411.8 (poor). There was a trend toward
increasing study methodological quality with date of publication
(Appendix 2B). Mean MCMS was highest with level I evidence
(56.7 8.22) (fair), followed by poor ratings with Level II
(48.0 7.59), Level III (37.6 8.81), and Level IV (29.3 6.84)
(Appendix 2C). Ninety percent of the studies in this review (74/82)
were rated poor and 10% (8/82) were rated fair, while there were no
good or excellent studies. The most common methodological
limitations within studies were clinical effect measurements (effect
sizes, relative or absolute risk reductions), number-needed-to-treat
calculations, alpha error and power calculations, randomization
methods, and blinding (Appendix 2D). Mean MCMS was similarly
poor in studies that reported a COI (35.711.6), denied a COI
(37.012.6), and did not report the presence or absence of a COI
(32.010.7). There was no signiﬁcant difference in MCMS between
studies that reported or denied the presence of a COI (P > 0.05).
Table IVb
Distribution of subjects across all generations of ACI. Duplicate study populations were not included in this review
Generation Numbers of studies
reporting technique
Number of subjects
undergoing technique
Number of knees
undergoing technique
Number of defects
undergoing technique
First generation PACI 50 3302 3341 3974
CACI 16 869 892 899
CCI 1 51 51 51
Second generation
(open vs arthroscopic)
Arthroscopic 28 363 1111 1199
Open 734
Second generation
(individual techniques)
MACI 6 159 161 182
Hyalograft C 11 542 542 593
BioSeed C 5 186 196 205
CaReS 2 36 36 37
ACI-Maix 1 62 62 62
Tissucol 1 25 25 29
Chondron 1 30 30 32
Novocart 3D 1 30 32 32
Atellocollagen gel 1 27 27 27
Third generation Third generation 1 8 8 8
MACI (matrix-associated or matrix-induced ACI).
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There were 305 failures overall (mean 5.8% failure rate over all
subjects analyzed) (Table VIa). Failure rate was highest after PACI.Table V
Subject and defect demographic data
Patient and defect characteristics (Number of subjects with
available data)
Mean age (years) 33.4 (5050)
Mean body mass index (kg/m2) 25.0 (1227)
Gender*
Male 62% (3035)
Female 38% (1870)
Workers’ compensation subjects 274
Mean defect size (cm2) 4.77 (6049)
First-generation PACI 5.05 (3941)
First-generation CACI 4.47 (899)
Second generation 4.12 (1201)
Third generation 1.3 (8)
Defect locationy
Medial femoral condyle 50% (2069)
Patella 16% (696)
Lateral femoral condyle 16% (660)
Trochlea 16% (651)
Tibial plateau 2% (84)
Fixation of cells/scaffold
PACI suture and ﬁbrin gluez (40)x
PACI suture onlyz (9)
CACI suture and ﬁbrin gluek (16)
Second-generation ﬁbrin glue only (12)
Second-generation suture only (2)
Second-generation suture and ﬁbrin glue (5)
Second-generation press-ﬁt (6)
Third-generation proprietary adhesive (1)
CPM utilized post-operatively (PACI) 66% (2174){
CPM utilized post-operatively (CACI) 13% (200)#
CPM utilized post-operatively (second gen) 76% (830)**
CPM utilized post-operatively (third gen) 100% (8)
* Within eight studies (n¼ 533), gender was not reported.
y The intra-articular defect location was reported in 68% (n¼ 4160) of all defects
within all studies (n¼ 6080).
z One study did not report type of PACI ﬁxation.
x One study did not report type of CACI ﬁxation.
k Number of studies reporting type of ﬁxation.
{ CPM utilization not reported in 20% of subjects (11 studies, 714 subjects).
# CPM utilization not reported in 44% of subjects (two studies, 394 subjects).
** CPM utilization not reported in 10% of subjects (three studies, 123 subjects).Failure rates after PACI, CACI, second-generation, and all-arthro-
scopic, second-generation ACI were 7.7%, 1.5%, 3.3%, and 0.83%,
respectively. Among workers’ compensation subjects, failure rate
was 23%. Reasons for failure generally involvedmagnetic resonance
imaging (MRI) or arthroscopic evidence (at planned or unplanned
re-operation) of delamination, lack of ﬁll, violation of subchondral
bone, repeat ACI, or total knee arthroplasty (Table VIb). Failure rate
after arthrotomy-based ACI (ﬁrst-generation PACI, ﬁrst-generation
CACI, open second-generation ACI, and third-generation) was 6.1%
vs a failure rate of 0.83% for all-arthroscopic, second-generation ACI.Re-operations after ACI
Re-operation was common, with one out of three patients
requiring a re-operation after ACI (33%). There were 1756 re-oper-
ations after all ACI techniques (33.3% of all subjects) (Table VIIa).
Unplanned re-operation rate was highest after PACI (27%). Mean
time to re-operationwas 17 months. After ﬁrst-generation CACI, 5%
of all CACI subjects underwent unplanned re-operation. Mean time
to re-operationwas 14.7months. After second-generation ACI, 5% of
all second-generation subjects underwent unplanned re-operation.
Mean time to re-operation was 15.7 months. Further, after all-
arthroscopic, second-generation ACI, 1.3% of all second-generation,
all-arthroscopic subjects underwent unplanned re-operation. After
third-generation ACI, there were no re-operations reported.
Debridement of graft hypertrophy or graft delamination was the
most common reason for re-operation (Table VIIb), followed by lysis
of adhesions, and manipulation under anesthesia. The unplanned
re-operation rate for arthrotomy-based ACI was 20% vs 1.4% for
all-arthroscopic, second-generation ACI.Table VIa
Failure rate of ACI generations
Generation of ACI Failure rate %
(number of failures)
Time to failure, years
(number of subjects
with this data available)
First-generation PACI 7.7% (254) 1.77 (132)
First-generation CACI 1.5% (13) 2.00 (2)
Second-generation ACI 3.3% (36) 1.73 (18)
All-arthroscopic ACI 0.83% (3) 3.67 (3)
Third-generation ACI 25% (2) nr
Workers’ compensation
ACI cases
23% (33) nr
Overall ACI 5.8% (305) 1.8 (152)
nr (Not reported).
Table VIb
Reasons for failure following ACI
Generation of ACI Reasons for failure (number of subjects meeting study deﬁnition of failure)
First-generation PACI MRI evidence of delamination, >25% of grafted defect area removal due to symptoms; repeat ACI, unicondylar or total knee arthroplasty24
Surgical re-treatment that violated subchondral bone, repeat ACI, complete delamination or removal of ACI, or failure to improve in
three consecutive 6-month follow-up periods (via modiﬁed Cincinnati score)29
Re-operation requiring graft removal, violation of subchondral bone, or conﬁrmation of no graft ﬁll16,69
No clinical improvement or graft failure88
Revision with arthroplasty31
Bare bone seen in <50% of repair (partial) or >50% of repair (complete)56
Poor clinical outcomes with evidence of graft failure due to delamination, ﬁbrous or ﬁbrocartilage repair, or detached graft on
MRI or arthroscopy71
Remainder of variable reasons for failure
First-generation CACI Re-intervention for inadequate ﬁll, graft delamination, degeneration requiring violation of subchondral bone plate or repeat ACI5
Insufﬁcient regenerative cartilage4
Severely abnormal ICRS score due to limited range-of-motion, painful retropatellar crepitation, persistent effusions39
Deterioration of knee condition upon exam, mechanical symptoms. Suboptimal defect ﬁll, delamination, clefts, ﬁssures53
Not reported52,59
Second-generation ACI
All-arthroscopic ACI
Need for further surgery due to continued pain, swelling, leading to total knee arthroplasty25
Re-operation to remove graft, repeat ACI, or violate subchondral bone70
Needed re-operation because of symptoms due to primary defect14,21
Insufﬁcient regenerative cartilage4
Severely abnormal ICRS score due to limited range-of-motion, painful retropatellar crepitation, persistent effusions39
Subsequent procedure violating subchondral bone for same defect, re-implantation, delamination, or removal34
Revision to total knee arthroplasty
Graft removal11
Not reported57,61,72,77
Needed re-operation because of symptoms due to primary defect14
Third-generation ACI Not reported
ICRS (International Cartilage Repair Society).
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The most common complication following ﬁrst- and second-
generation ACI was graft/periosteal hypertrophy (Table VIII). Most
cases of hypertrophy occurred following PACI vs CACI, second-
generation and third-generation ACI. Twenty-ﬁve percent of grafts
delaminated following third-generation ACI (n¼ 2 of 8 cases
overall). Excluding third-generation, most cases of delamination
occurred following ﬁrst-generation PACI. There were similar rates
of delamination between ﬁrst-generation CACI and second-gener-
ation. All cases of arthroﬁbrosis occurred following arthrotomy-
based ACI (ﬁrst-generation PACI, CACI, and open second-generation
ACI). All superﬁcial and deep infections occurred following
arthrotomy-based ACI. All deep vein thromboses occurred
following ﬁrst-generation ACI. One pulmonary embolus occurred
following ﬁrst-generation PACI. No deaths occurred following ACI.
First vs second vs third-generation ACI
Failure was signiﬁcantly more frequent following ﬁrst-generation
ACI (6.4%) vs second-generation (3.3%) (Z¼ 3.92; P< 0.001). Although
25% of third-generation ACI cases failed (due to graft delamination),
only eight total cases were analyzed (two of eight). Unplanned re-op-
erations were signiﬁcantly more frequent following ﬁrst-generationTable VIIa
Re-operation rates following ACI
Generation of ACI Number of re-operations
(% of all subjects)
% Of subjects within each
generation undergoing
unplanned re-operation
N
r
(
First-generation PACI 1200 (36%) 27% 8
First-generation CACI 345 (40%) 5% 4
Second-generation ACI 211 (18%) 5% 6
All-arthroscopic ACI 54 (15%) 1.4% 5
Third-generation ACI 0 n/a 0
nr (not reported); n/a (not applicable).ACI (23%) vs second-generation (6%) (Z¼ 13.2; P< 0.001). Hyper-
trophy was signiﬁcantly more common following ﬁrst-generation
(15%) vs second-generation (1.2%) (Z¼ 12.5; P< 0.001). Delamination
was signiﬁcantly more common following ﬁrst-generation ACI (4.2%)
vs second-generation (1.5%) (Z¼ 4.25; P< 0.001). Arthroﬁbrosis was
signiﬁcantly more common following ﬁrst-generation ACI (2.9%) vs
second-generation (1%) (Z¼ 3.58; P¼ 0.00022).
PACI vs CACI
Failure was signiﬁcantly more frequent following PACI (7.7%) vs
CACI (1.5%) (Z¼ 6.64; P< 0.001). Unplanned re-operations were
signiﬁcantly more frequent following PACI (27%) vs CACI (5%)
(Z¼ 13.8; P< 0.001). Hypertrophy was signiﬁcantly more common
following PACI (18%) vs CACI (3%) (Z¼ 11.1; P< 0.001). Delamina-
tion was signiﬁcantly more common following PACI (5%) vs CACI
(2%) (Z¼ 3.85; P< 0.001). Arthroﬁbrosis was similarly common
between PACI (3%) and CACI (2%) (Z¼ 1.59; P¼ 0.056).
Arthrotomy-based ACI vs all-arthroscopic ACI
Failure was signiﬁcantly more frequent following open arthrot-
omy-based ACI (6.1%) vs all-arthroscopic ACI (0.83%) (Z¼ 4.17;
P< 0.001). Unplanned re-operations were signiﬁcantly moreumber of unplanned
e-operations
% of all re-operations)
Number of planned
re-operations
(% of all re-operations)
Mean time to re-operation,
months (number of subjects
with this data available)
99 (75%) 301 (25%) 17.3 (543)
0 (12%) 305 (88%) 14.7 (161)
0 (28%) 151 (72%) 15.7 (90)
(9%) 49 (91%) *nr
0 n/a
Table VIIb
Reasons for re-operation
Reason for re-operation First-generation
PACI
First-generation
CACI
Second-generation
ACI
Second-gen ACI
(all-arthroscopic)
Third-generation
ACI
Debride hypertrophy or delamination 381 26 2 2 0
Lysis of adhesions 57 1 * * 0
Manipulation under anesthesia 46 6 1 * 0
Partial meniscectomy 25 * * * 0
Revision ACI 20 4 2 1 0
Synovectomy 22 * 4 * 0
Loose body removal 23 * * * 0
Microfracture 20 * * * 0
Carbon ﬁbre graft implantation * * * * 0
Total knee arthroplasty 9 * 3 1 0
Tibial tubercle osteotomy 8 * * * 0
Osteochondral allograft 4 * * * 0
Osteochondral autograft 3 * 1 1 0
Valgus high tibial osteotomy 1 * * * 0
Patellofemoral arthroplasty 1 * * * 0
Unicompartmental knee arthroplasty 1 * * * 0
Patellectomy 1 * * * 0
ACL reconstruction * * * * 0
Removal of hardware * * 2 * 0
All re-operation data based on available data within individual studies (both planned and unplanned re-operations).
* Not reported within all individual studies within stated generation.
J.D. Harris et al. / Osteoarthritis and Cartilage 19 (2011) 779e791 785frequent following arthrotomy-based ACI (20%) vs all-arthroscopic
ACI (1.4%) (Z¼ 8.77; P< 0.001). Hypertrophywas signiﬁcantlymore
common following arthrotomy-based ACI (13%) vs all-arthroscopic
ACI (<1%) (Z¼ 12.1; P< 0.001). Delamination was signiﬁcantly
more common following arthrotomy-based ACI (3.9%) vs all-
arthroscopic ACI (<1%) (Z¼ 3.33; P¼ 0.00053). Arthroﬁbrosis was
signiﬁcantly more common following arthrotomy-based ACI (2.7%)
vs all-arthroscopic ACI (zero cases of arthroﬁbrosis following all-
arthroscopic ACI) (Z¼ 3.17; P¼ 0.00088).
Discussion
The purpose of this study was to report and compare the failure,
re-operation, and complicationproﬁles of thedifferent generationsof
ACI.We conﬁrmed our hypotheses that complications, re-operations,
and failures aremore commonwith ﬁrst-generation ACI, particularly
with arthrotomy compared to all-arthroscopic techniques.
ACI is a safe technique used for treatment of chondral defects in
theknee. Failure rates after all generations of ACIwere low (1.5%after
CACI, 3.3% after second-generation ACI, and 7.7% after PACI). The
variability in study deﬁnition of failure is an important preface,
though generallywas reported as re-operation due to symptoms andTable VIII
Complications after ACI (diagnosed by clinical exam, MRI, and arthroscopy)
Complication First-generation PACI
(% of all PACI subjects)
First-generation CA
(% of all CACI subje
Hypertrophy of graft
(or periosteum, when applicable)
607 (18%) 24 (3%)
Delamination 159 (5%) 18 (2%)
Arthroﬁbrosis 102 (3%) 21 (2%)
Superﬁcial infection (resolution
with antibiotics)
8 (<1%) 5 (1%)*
Septic knee joint (requiring arthrotomy,
irrigation, and debridement)
2 (<1%) 0
Deep vein thrombosis 3 (<1%) 3 (<1%)
Pulmonary embolus 1 (<1%) 0
Deaths 0 0
All complications reported based on data available within all individual studies within e
* One superﬁcial infection occurred following planned second-look arthroscopy.requiring either graft removal, re-treatment with ACI, or violation of
the subchondral bone with metallic arthroplasty or marrow-stim-
ulation techniques. Based on the latter deﬁnition, failures tended to
occur due to grafts either partially or completely delaminating or
insufﬁcient ﬁll. Delaminations may be due to new traumatic injury
(e.g., rehabilitation non-compliance) or atraumatic ﬂap formation
secondary to insufﬁcient integration to the normal surrounding
peripheral cartilage or the underlying subchondral bone. Failures
occurred around 18e24months after ACI in all groups. This conﬁrms
ﬁndings of other authors, stating that subjects who have poor or
even fair clinical outcomes by 2 years post-operatively all eventually
fail89. Patients with good or excellent results tended to remain
satisﬁed with their outcome, with three-quarters of subjects
reporting their status as good as or better than prior years90. A
subgroup of patients that have knownpoorer outcomeswith certain
medical conditions and following certain surgeries is the Workers’
Compensation patient, who was found to have a signiﬁcantly
increased risk of failure vs non-WC patients91e93.
Re-operations are frequent after ACI, occurring in a third of the
subjects. Although many are planned second-look arthroscopy,
symptomatic hypertrophy of the periosteum in ﬁrst-generation
PACI prompted the majority of unplanned re-operations. The use ofCI
cts)
Second-generation ACI
(% of all second-
generation subjects)
Second-generation ACI
(all-arthroscopic)
(% of all second-
generation all-AKS
subjects)
Third-generation ACI
(% of all third-generation
subjects)
13 (1%) 2 (<1%) 0
17 (2%) 3 (<1%) 2 (25%)
10 (1%) 0 0
3 (<1%) 0 0
1 (<1%) 0 0
0 0 0
0 0 0
0 0 0
ach generation.
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chondrocyte-seeded scaffolds has signiﬁcantly reduced the inci-
dence of hypertrophy. The presence of hypertrophy does not always
necessitate re-operation. Mechanical symptoms, such as catching,
or a new-onset effusion may prompt a subsequent arthroscopic
surgical procedure to shave the hypertrophied periosteum88.
Although shaving seems to be a simple and effective solution to the
problem, some authors believe that it leads to worse clinical
outcomes after surgery56. However, in a large “good clinical prac-
tices” (GCP) clinical trial, subsequent surgeries such as arthroscopic
debridement have not been associated with worse clinical
outcomes29. As our review analyzed failures and not clinical
outcomes, we were unable to conﬁrm any of these ﬁndings.
The timing of hypertrophy development and its etiology are not
completely understood. Althoughmost authors report the presence
of hypertrophy within the ﬁrst year post-operatively56,87,88, our
study was unable to conﬁrm or deny this ﬁnding as many of the
studies did not assess for hypertrophy in asymptomatic subjects
and used dissimilar methods of detection of hypertrophy (MRI vs
arthroscopic knee surgery (AKS)). Although some authors theorize
that the mechanical frictional stimulation of the periosteum leads
to overgrowth56, other believe that it is the underlying restoration
cartilage tissue that is pushing the periosteum intra-articularly78.
Further, since the cambium layer (facing the defect) has intrinsic
ability to produce neocartilage due to the presence of growth
factors and chondrocyte precursor cells, many believe that the
periosteum simply grows independent of the underlying cells or
mechanical stimulation55.
Re-operation after ACI may also be related to the arthrotomy
used to implant cells. The rate of adhesions and arthroﬁbrosis was
much lower in arthroscopic second-generation techniques vs open
ﬁrst- and second-generation techniques. As it is well-known that if
stiffness is to occur, it generally occurs within the ﬁrst 2e4 months.
Many authors use a standardized CPM protocol post-operatively
(62 out of 82 studies in this review). The use of Sepraﬁlm (Genzyme
Biosurgery, MA, USA)94,95 is also a method to reduce adhesions. The
latter method is commonly used in general, cardiac, and gyneco-
logic surgery. However, the prevalence of use in orthopedic surgery,
speciﬁcally knee surgery, is unknown. Nevertheless, many authors
used a post-operative immobilization protocol in a cylinder cast or
plaster of Paris splint for 10 days, followed by range-of-motion
upon cast removal12,32,72,79,83. This, however, did not result in an
increase in incidence of arthroﬁbrosis. Manipulation under anes-
thesia with or without arthroscopic lysis of adhesions was an
effective treatment utilized often in the studies in this review.
This study is not without limitations as there is a wide range of
bias sources within the studies analyzed. Only a small number of
randomized clinical trials (Level I evidence) are available in the
literature, and even their methodological quality is poor96. Based
on the MCMS scores of the studies within this review, the meth-
odological quality of ACI studies is improving with time (Appendix
2B). Nevertheless, there were clear deﬁciencies in certain areas of
even the highest level of evidence. Of the 82 studies in this review,
90% were rated poor (74/82) and 10% were rated fair (8/82), while
there were no good or excellent studies. Although the use of the
MCMS has not been validated in evaluation of methodological
quality of cartilage repair studies, it has been used in the evaluation
of tendinopathy outcomes. One item not included in theMCMS that
may require addition to future methodological quality assessment
tools is the presence or absence of a ﬁnancial COI. There was no
difference in study quality via MCMS in studies that reported,
denied, or did not report the presence or absence of a COI. This
ﬁnancial incentive bias may inﬂuence the reporting of adverse
events within a technique. Further, ﬁrst-generation ACI techniques
were signiﬁcantly more likely to declare a COI than second-generation studies. However, the lack of transparency in reporting
the presence or absence of a COI was not signiﬁcantly different
between generations.
Although the purpose of our study was not a comparison of
clinical outcomes, it was a comparison of complication, failure, and
re-operation rates between different generations of ACI. High-
quality randomized controlled clinical trials are required to
demonstrate if a difference exists between different ACI generations
with regard to clinical, radiographic, or histologic outcomes.
Detailed quality reporting is vital to comparison between studies
and techniques. Heterogeneous subject demographic datawas seen
not only between studies, but also within studies. This does not
allow for an equal comparison truly evaluating techniques. Deﬁni-
tions of failure, symptomatic and asymptomatic hypertrophy,
delamination, arthroﬁbrosis, and stiffness are not uniform across
studies and therefore prevent accurate comparison of techniques.
There was signiﬁcant performance bias in that dissimilar “intra-
group” ACI techniques were used (speciﬁcally source of periosteal
graft, type of suture for ﬁxation used, use of ﬁbrin adhesive, the
brand of collagen-membrane cover, the cell culturing facility used,
and the ﬁxation used for many of the second-generation scaffolds
([some required subchondral bone drill-hole-suture-based ﬁxation
and some press-ﬁt]). Further, although used in Europe, Asia, and
Australia, second- and third-generation techniques are not
currently available in the United States. Dissimilar concurrent
techniques confounds our results in that many studies performed
concurrent anterior cruciate ligament (ACL)-reconstruction,
meniscus repair, meniscectomy, and patellofemoral realignment
and coronal plane high tibial or distal femoral realignment
osteotomies.
Although longer follow-up is necessary for the assessment of
the durability of a surgical technique and a survivorship analysis,
the purpose of our study was to determine complications across all
time points in the post-operative course after ACI. Therefore,
studies with even short follow-up and case reports were included
and analyzed. Detection bias was present in that different outcome
measures were used to identify complications (clinical, radio-
graphic, arthroscopic, histological). Further, different clinical
outcomes instruments, different MRI and X-ray techniques, and
different histological evaluation instruments were used across
studies. Surgeons were used as evaluators post-operatively in the
majority of studies. Planned second-look arthroscopy vs symptom-
driven arthroscopy is a major confounding factor in that, in and of
itself, is not benign and can alter future outcomes. It is the diag-
nostic gold standard for intra-articular pathology and therefore,
may detect asymptomatic conditions that otherwise would not
have been reported. Not all studies performed second-look
arthroscopy and many that did failed to report whether it was
planned a priori or unplanned and performed due to symptoms.
Although we believe that this study may report the largest
number of subjects undergoing ACI in the currently available
literature, it is deﬁcient in many areas, highlighting a need for
future improvements in reporting. The greatest shortcoming of the
ACI literature is the heterogeneity in outcomes reporting and study
transparency. Nearly every study lacked at least one (and usually
several) component of quality analysis of a therapeutic study and
the response of its subject to a treatment.
Conclusions
Failure rate after all generations of ACI is low (1.5e7.5%). Failure
rate is highest with ﬁrst-generation PACI, and lower with ﬁrst-
generation CACI and second-generation ACI techniques. One out of
three ACI patients underwent a re-operation. Unplanned re-oper-
ations are seen most often following PACI. Hypertrophy and
Enrollment rate <80% 6
Enrollment rate >80% 9
2) Power Not reported 0
>80%, methods not described 3
J.D. Harris et al. / Osteoarthritis and Cartilage 19 (2011) 779e791 787delamination are most commonly seen after PACI. Arthroﬁbrosis is
most commonly seen after arthrotomy-based ACI. Use of
a collagen-membrane cover, second-generation techniques, and
all-arthroscopic, second-generation approaches have reduced the
failure, complication, and re-operation rate after ACI. Second-
generation techniques are not currently available for use in the
United States.>80%, methods described 6
3) Alpha error (a) Not reported 0
<0.05 3
<0.01 6
4) Sample size Not stated or <20 0
20e40 3
41e60 6
>60 9
5) Randomization Not randomized 0Contributions
All authors listed above have made substantial contributions to
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approval of the version to be submitted.Modiﬁed/partial
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Blinded 4
Complete
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6) Follow-up Short-term (<6 months)
Patient retention <80% 0
Patient retention 80e90% 2
Patient retention >90% 4
Medium-term (6e24 months)
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6
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Single 2Appendix 1. Individual variables recorded for each study
analyzed
Study data Subject data Technique data Adverse event data
Author Number of subjects ACI generation(s) Failures
used
Publication
date
Number of knees Concomitant
surgeries
Deﬁnition of failure
Journal title Number of defects Cover used Time to failure
Level of
evidence
Number of ACI
procedures
Open vs
arthroscopic
Complications
COI Gender Graft ﬁxation Delamination
Age Hypertrophy
Body mass index
(kg/m2)
Dx of hypertrophy
(MRI vs AKS)
Duration of
follow-up
Chondromalacia
Workers’
compensation status
Adhesions
Prior surgeries Loose bodies
Preoperative duration
of symptoms
Meniscus tear
Defect size (cm2) Infection
Defect location Patellofemoral
maltracking
Post-operative
weight-bearing status
Arthroﬁbrosis
Post-operative
continuous
passive motion
Plica
Hemarthrosis
Deep vein thrombosis
Pulmonary embolus
Re-operations
Reasons for
re-operation
Time to re-operation
kg (Kilogram); m (meter); cm (centimeter); Dx (diagnosis).Appendix 2A. MCMS e scaled score of 0e100
1) Inclusion criteria Not described 0
Described without %’s given 3Double 4
Triple 6
9) Similarity in treatment No 0
Similar co-interventions 3
No co-interventions 6
10) Treatment description None 0
Fair 3
Adequate 6
11) Group comparability Not comparable 0
Partially comparable 3
Comparable 6
12) Outcome assessment Written assessment by patient
with assistance
0
Written assessment by patient
without assistance
2
Independent investigator 4
Recruited patients 6
13) Description of rehabilitation
protocol
Not reported 0
Not adequately described 2
Well described 4
14) Clinical effect measurement Effect size
Not reported 0
<50% 2
50e75% 4
>75% 6
or Relative risk reduction
Not reported 0
<25% 3
(continued on next page)
Appendix 2A. (continued)
>25% 6
or Absolute risk reduction
Not reported 0
<10% 3
>10% 6
15) Number of patients to treat Not reported 0
Reported 4
Excellent (85e100), good (70e84), fair (55e69), poor (<55).
J.D. Harris et al. / Osteoarthritis and Cartilage 19 (2011) 779e791788Appendix 2B. Mean MCMS per yearAppendix 2C. Mean MCMS per level of evidenceAppendix 2D. Mean MCMS per each item on the instrumentSupplementary data
Supplementary data related to this article can be found online at
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